Domain Therapeutics is a biopharmaceutical company dedicated to the discovery and early development of new drug candidates targeting transmembrane receptors, in particular, G Protein-Coupled Receptors (GPCRs), one of the most important classes of drug targets. Domain identifies and develops candidates (allosteric modulators and biased ligands) through its innovative approach and
technologies. Domain has three revenue-generating pillars within its innovative business model:
1) collaboration with pharma companies for the discovery of new molecules
2) out-licensing of its bioSens-All™ technology
3) creation of asset-centric vehicles for the development of its internal pipeline of preclinical candidates for central nervous system disorders, cancer and rare diseases.
These asset-centric companies attract investment for focused development and exit is
through a trade sale at an appropriate inflection point.
For more information, please visit
https://www.domaintherapeutics.com/